ClinicalTrials.gg
CompletedNCT06264817LyberTUpdated Oct 14, 2026

Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema.

An interventional study of MOBIDERM Autofit Armsleeve and Compressive bandaging in Lymphedema of Upper Limb, sponsored by Thuasne. Completed at 2 sites in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Thuasne · Not applicable, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.

Enrollment
23rd of 45
40 · median 40
Started
2024
with 8 others
No phase
44 of 65
11 open now
Registered
30th of 65
by date

Among the 65 studies in Lymphedema with a site in Turkey, this one is the 23rd largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2024, is one of 44 with no phase, and was the 30th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Lymphedema with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess compared to the compression bandages to manage the volume of upper limb lymphedema in patients with breast cancer related lymphedema

Read the detailed description

The overall range of compression devices dedicated to lymphedema treatment offers standard or custom-made garments and different types of bandages. Indeed, bandages are not easy to put on, requiring specific patient's skills and/or assistance which is not optimal for long-term compliance. Moreover, they are composed of several layers forming a quite bulky multilayer bandage that limits limb function and does not contribute to a better quality of life. For all these reasons described, even if bandaging is the current reference of lymphedema treatment, they have disadvantages.

The day-time elastic compressive armsleeves are proposed as an alternative to bandages. However, whatever their standard or custom-made design, they cannot adapt to limb volume/morphology evolution on the long-term management of this chronic disease because they are not adjustable. Therefore, as the comfort of treatment is very important in improving compliance, armsleeves are sometimes poorly tolerated by patients resulting in decreasing compliance to treatment plan.

In order to optimize treatment of lymphedema efficacy, THUASNE developed the standard Auto-Adjustable Armsleeve using the MOBIDERM technology.

03

Conditions studied

  • Lymphedema of Upper Limb

Browse trials for

Keywords

  • Lymphedema of upper limb
  • Compression garments
  • lymphedema management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral secondary upper limb lymphedema of stage II or III according to the criteria defined by the International Society of Lymphology, following breast cancer
  • Volume difference between affected and healthy arm ≥ 10%
  • Affected arm that fits with one of the 6 standard sizes of the Auto- Adjustable MOBIDERM Autofit armsleeve provided.
  • Signed prior to any study-mandated procedure.

Exclusion criteria

Exclusion Criteria:

  • Stage I lymphedema or located in several places.
  • Patients for whom compression is .
  • Lymphedema associated with active cancer needing acute chemotherapy or having recurrence or .
  • Motor and sensitive neurological deficiency / psychiatric or addictive disorders
  • Pregnant or breastfeeding patient
  • Patient intolerant to MOBIDERM Autofit or known allergies to the components used.
  • Participation to any other clinical study which has an impact on the different endpoints
  • Vulnerable patient, adults being the object of a legal protective measure or enable to express their consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Control group : compressive bandaging

    Control group : compressive bandaging: * Intensive phase (3 weeks): compressive bandaging (day and night-time) according to the usual practice * Maintenance phase (5 weeks): usual compression sleeve during the day + Self bandages at night

    Device: Compressive bandaging

  • Experimental
    Intervention group: MOBIDERM Autofit Armsleeve

    Intervention group: MOBIDERM Autofit Armsleeve * Intensive phase (3 weeks): MOBIDERM Autofit Armsleeve (day and night-time) * Maintenance phase (5 weeks): usual compression sleeve during the day + MOBIDERM Autofit Armsleeve at night

    Device: MOBIDERM Autofit Armsleeve

Interventions

  • DeviceMOBIDERM Autofit Armsleeve

    In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks. During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks

  • DeviceCompressive bandaging

    In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks. During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks

06

What researchers measure

Primary outcomes

  1. Volume excess variation

    The primary endpoint of this study is to compare between both groups the volume evolution of the upper limb between inclusion and the end of the study. Limb Volume is calculated with truncated cone formula.

    Time frame: 8 weeks

Secondary outcomes

  1. Resource consumption

    Resource consumption is measured by time of transports (travel time in minutes).

    Time frame: 3 and 8 weeks

  2. Resource consumption

    Resource consumption is measured by number of used medical devices (number).

    Time frame: 3 and 8 weeks

  3. Resource consumption

    Resource consumption is measured by the number and duration (per minute) of lymphedema-related healthcare consultations and hospitalizations.

    Time frame: 3 and 8 weeks

  4. Lymphedema related Quality of life (QoL)

    The evolution of QoL is measured by LYMQOL ARM self-questionnaire and specific questions. This tool is designed as patient-completed questionnaire. The questions cover four domains : symptoms, body image/appearance, function, mood. Each item in each domain is scored : not at all (1), a little (2), Quite a bit (3), A lot (4). Specific questions are about patient's perception of benefit

    Time frame: 3 and 8 weeks

  5. Doctors' opinion on improving the patient's health condition

    Doctors' opinion on improving the patient's health condition caused by lymphedema is measured by the CGI-I questionnaire (Clinical Global Improvement Impression). This questionnaire allows doctors to evaluate the improvement of patients. The scale has 7 levels from "very strongly improved"(better outcome) to "very strongly aggravated"(worse outcome).Intermediate levels are: " Significantly improved " ; " Slightly improved " ; " No improvement " ; " Slightly aggravated " ; " Seriously aggravated "

    Time frame: 3 and 8 weeks

  6. Patient's opinion on Global Impression of Change

    Patient's opinion on Global Impression of Change about her general condition is measured by the PGI-C questionnaire (Patient's opinion on Global Impression of Change). The scale has 7 levels from "no change or condition has got worsed"(worse outcome) to "a great deal better, and a considerable improvement that has made all the difference ( better outcome)". Intermediate levels are: "almost the same, hardly any change at all"; "a little better, but no noticeable change", "somewhat better, but the change has not made any real difference"; "moderately better, and a slight but noticeable change"; "better, and a definite improvement that has made a real and worthwhile difference

    Time frame: 3 and 8 weeks

  7. Satisfaction about the device

    Patient's satisfaction with regards to MOBIDERM® Autofit vs bandages is measured by a satisfaction questionnaire. This questionnaire is focused on the product positioning with a question with 4 levels: very easy (better outcome), easy, difficult, very difficult (worse outcome) and the comfort with a question with 4 levels very comfortable (better outcome), comfortable, uncomfortable, very uncomfortable (worse outcome).

    Time frame: 8 weeks

  8. The safety

    Number and type of serious and non-serious Adverse Device Effects (ADE).

    Time frame: 8 weeks

  9. Compliance to treatment

    The compliance to treatment (day-time and night-time) is reported by the physician in the e-CRF according to the patient diary. The compliance is measured in number of days and or nights when the device is worn and the average wearing time

    Time frame: 8 weeks

  10. General quality of life (QoL)

    The evolution of QoL is measured by the EQ5D3L questionnaire completed by the patient. The EQ-5D3L questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems (Level 1 is coded as a '1'), moderate problems (Level 2 is coded as a '2'), and extreme problems (Level 3 is coded as a '3'). The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS). The EQ VAS is measured by VAS : 100 corresponds to the best health and 0 to the the worst health.

    Time frame: 3 and 8 weeks

  11. Skin elasticity

    The evolution of skin thickness and elasticity is measured by ultrasound

    Time frame: 3 and 8 weeks

  12. Ttissue induration

    The evolution of tissue induration is measured via the skinfibrometer (Delfin Tech).

    Time frame: 3 and 8 weeks

07

Study locations

2 sites
  • Pinar BORMAN
    Ankara, Turkey, Turkey (Türkiye)
  • ANKARA
    Ankara, Turkey (Türkiye)
08

References and documents

Publications

  • Ochalek K, Kurpiewska J, Gradalski T. Adjustable Compression Wraps (ACW) vs. Compression Bandaging (CB) in the Acute Phase of Breast Cancer-Related Arm Lymphedema Management-A Prospective Randomized Study. Biology (Basel). 2023 Mar 31;12(4):534. doi: 10.3390/biology12040534. PubMed 37106735 ↗
  • Mestre S, Calais C, Gaillard G, Nou M, Pasqualini M, Ben Amor C, Quere I. Interest of an auto-adjustable nighttime compression sleeve (MOBIDERM(R) Autofit) in maintenance phase of upper limb lymphedema: the MARILYN pilot RCT. Support Care Cancer. 2017 Aug;25(8):2455-2462. doi: 10.1007/s00520-017-3652-5. Epub 2017 Mar 9. PubMed 28281052 ↗
  • Borman P, Koyuncu EG, Yaman A, Calp E, Koc F, Sargut R, Karahan S. The Comparative Efficacy of Conventional Short-Stretch Multilayer Bandages and Velcro Adjustable Compression Wraps in Active Treatment Phase of Patients with Lower Limb Lymphedema. Lymphat Res Biol. 2021 Jun;19(3):286-294. doi: 10.1089/lrb.2020.0088. Epub 2020 Dec 2. PubMed 33270499 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2025, 15 months.

Of 197 interventional studies with no phase under Lymphedema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's 15 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Mar 2025 → Jun 2025 and completion Apr 2025 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 20, 2024
StartActual
Mar 15, 2024
Primary completionActual
Jun 27, 2025was Mar 2025
CompletionActual
Aug 26, 2026was Apr 2025
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 14, 2026
Sites
1 site added, 1 site removed
Show site
  • Pinar BORMAN · Ankara, Turkey (Türkiye)
Show 1 removed
  • Pinar BORMAN · Ankara, Turkey
Oct 14, 2026
Primary completion
Mar 15, 2025→Jun 27, 2025 (actual)
Oct 14, 2026
Study completion
Apr 15, 2025→Aug 26, 2026 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Pinar BORMAN · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Pinar BORMAN · Ankara, Turkey
    Primary completion Mar 15, 2025→Jun 27, 2025 (now actual)
    Study completion Apr 15, 2025→Aug 26, 2026 (now actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06264817
Lead sponsor
Thuasne
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 15, 2024
Primary completion
Jun 27, 2025
Completion
Aug 26, 2026
Last update
Oct 14, 2026

Study contacts

Burcu DUYUR ÇAKIT
principal investigator · Ankara Training and Research Hospital Turkey

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion